These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 24790832)
1. Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010. Ghanname I; Ahid S; Berrada G; Belaiche A; Hassar M; Cherrah Y Springerplus; 2014; 3():192. PubMed ID: 24790832 [TBL] [Abstract][Full Text] [Related]
2. Trends in the use of antiasthmatic medications in Morocco (1999-2010). Ghanname I; Ahid S; Berrada G; Belaiche A; Hassar M; Cherrah Y Springerplus; 2013 Dec; 2(1):82. PubMed ID: 23519830 [TBL] [Abstract][Full Text] [Related]
3. Trends in antihypertensives use among Moroccan patients. Berrada El Azizi G; Ahid S; Ghanname I; Belaiche A; Hassar M; Cherrah Y Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1067-73. PubMed ID: 22585420 [TBL] [Abstract][Full Text] [Related]
4. [Generic drugs and the consumption trends of antihypertensives in Morocco]. Berrada El Azizi G; Ahid S; Ghanname I; Belaiche A; Hassar M; Cherrah Y Therapie; 2013; 68(5):303-12. PubMed ID: 24225041 [TBL] [Abstract][Full Text] [Related]
5. [Not Available]. El Azizi GB; Ahid S; Ghannam I; Belaiche A; Hassar M; Cherrah Y Therapie; 2013; 68(5):303-12. PubMed ID: 27393184 [TBL] [Abstract][Full Text] [Related]
6. [Consumption analyze of the antihypertensive drugs in Morocco: period 1991-2005]. Soussi-Tanani D; Alaoui K; Belaiche A; Hassar M; Cherrah Y Therapie; 2008; 63(2):129-33. PubMed ID: 18561887 [TBL] [Abstract][Full Text] [Related]
7. Trends in the consumption and cost of antiepileptics in Morocco between 2008 and 2018. Cherkaoui G; Cheikh A; Razine R; Bnouhanna W; Regragui W; Benomar A; Cherrah Y Rev Epidemiol Sante Publique; 2022 Apr; 70(2):75-81. PubMed ID: 35337700 [TBL] [Abstract][Full Text] [Related]
8. Trends in attention deficit hyperactivity disorder drugs consumption, Israel, 2005-2012. Ponizovsky AM; Marom E; Fitoussi I Pharmacoepidemiol Drug Saf; 2014 May; 23(5):534-8. PubMed ID: 24610676 [TBL] [Abstract][Full Text] [Related]
9. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system. Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144 [TBL] [Abstract][Full Text] [Related]
10. Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000-2004). Ubeda A; Cardo E; Sellés N; Broseta R; Trillo JL; Fernández-Llimós F Soc Psychiatry Psychiatr Epidemiol; 2007 Mar; 42(3):181-8. PubMed ID: 17235443 [TBL] [Abstract][Full Text] [Related]
11. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO Value Health; 2012; 15(5):664-73. PubMed ID: 22867775 [TBL] [Abstract][Full Text] [Related]
12. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction. Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158 [TBL] [Abstract][Full Text] [Related]
13. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703 [TBL] [Abstract][Full Text] [Related]
14. Use of generic and essential medicines for prevention and treatment of cardiovascular diseases in Portugal. Gama H; Torre C; Guerreiro JP; Azevedo A; Costa S; Lunet N BMC Health Serv Res; 2017 Jun; 17(1):449. PubMed ID: 28662649 [TBL] [Abstract][Full Text] [Related]
15. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics? Sun J; Ren L; Wirtz V J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310 [TBL] [Abstract][Full Text] [Related]
16. Impact of European pharmaceutical price regulation on generic price competition: a review. Puig-Junoy J Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079 [TBL] [Abstract][Full Text] [Related]
18. The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka District, Serbia. Calasan J; Mijatović V; Horvat O; Varga J; Sabo A; Stilinović N Int J Clin Pharm; 2011 Apr; 33(2):246-51. PubMed ID: 21744192 [TBL] [Abstract][Full Text] [Related]
19. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary]. Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646 [TBL] [Abstract][Full Text] [Related]
20. Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan. Shibata S; Matsushita M; Saito Y; Suzuki T Ther Innov Regul Sci; 2018 Jul; 52(4):442-448. PubMed ID: 29714554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]